Fuji expands U.S. x-ray imaging operationsIn a strong indication that its x-ray film business is healthy and growing, Fuji Photo Film has embarked on a $300-million expansion of its manufacturing and distribution operations in Greenville, SC.
In a strong indication that its x-ray film business is healthy and growing, Fuji Photo Film has embarked on a $300-million expansion of its manufacturing and distribution operations in Greenville, SC. The project includes two new manufacturing facilitiesone for color photographic film and photographic paper, the other for x-ray film finishingand a major extension to the companys existing distribution center. Fuji plans to have the two new factories up and running early next year.
The move is expected to have a positive impact on Fuji Medical Systems conventional and digital x-ray imaging businesses and its enterprise-wide image and information management systems business, according to Clay Larsen, managing director of marketing for Fuji Medical Systems USA, which opened a U.S. manufacturing facility for digital medical imaging equipment and software last August. In particular, it should complement the companys efforts to help customers transition to a filmless environment.
Many customers dont want to treat computed radiography, digital x-ray, and PACS separately, Larsen said. They want to bundle film and CR or CR and PACS or put them all together into a plan to transition from film and lasers to CR and PACS. What a lot of people dont realize is that, as customers go to digital x-ray, there are going to have to be interim printing solutions before they go completely filmless.
© 2000 Miller Freeman, Inc., a United News & Media company.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Key MRI Findings Predictive of Treatment Response for Unresectable Hepatocellular Carcinoma
July 14th 2025For patients with unresectable hepatocellular carcinoma, a pre-treatment MRI finding of LI-RADS tumor in vein was associated with over an 86 percent lower likelihood of responding to transcatheter arterial chemoembolization (TACE) and targeted immunotherapy.